According to TipRanks.com, Porges is a 3-star analyst with an average return of 2.6% and a 48.4% success rate. Porges covers the Healthcare sector, focusing on stocks such as Opthea Limited Sponsored ADR, Vertex Pharmaceuticals, and Theravance Biopharma.
Currently, the analyst consensus on Pfizer is a Hold with an average price target of $45.55, implying a 3.5% upside from current levels. In a report issued on August 24, Morgan Stanley also reiterated a Hold rating on the stock with a $45.00 price target.
Pfizer’s market cap is currently $246.4B and has a P/E ratio of 18.80. The company has a Price to Book ratio of -34.45.
Based on the recent corporate insider activity of 41 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PFE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pfizer Inc. develops, manufactures and sells healthcare products, including innovative medicines and vaccines. Its key focus areas include oncology, inflammation & immunology, rare disease, vaccines and internal medicine. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Read More on PFE:
- Cloudflare: Will the Ascent Continue?
- Mizuho Securities Believes UnitedHealth (UNH) Still Has Room to Grow
- Wall Street Analysts Are Neutral on Top Financial Picks
- Analysts Are Neutral on Top Conglomerates Stocks: Johnson Controls (JCI)
- Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Humana (HUM) and Sanofi (OtherSNYNF)